New Jersey-based Immunomedics focuses on developing novel antibody drug conjugates (ADCs) for hard-to-treat cancers. At the end of April, its first ADC, Trodelvy (sacituzumab govitecan), received US Food and Drug Administration (FDA) accelerated approval in heavily pre-treated metastatic triple negative breast cancer (TNBC).
Now Trodelvy has been approved in the US, Immunomedics is tasked with having to launch its first ever drug during a pandemic.
Despite the challenges Covid-19 poses to a drug launch, Immunomedics chief commercial officer Brendan Delaney says the company never considered postponing the launch. Instead Immunomedics prepared as far in advance as possible to allow its sales and marketing team to effectively bring this drug to market.
Read the full story here.